Femalegra: Clinically Supported Female Libido Enhancement
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.30 | $43.00 (0%) | 🛒 Add to cart |
| 20 | $2.58 | $86.00 $51.60 (40%) | 🛒 Add to cart |
| 30 | $2.01 | $129.00 $60.20 (53%) | 🛒 Add to cart |
| 60 | $1.43 | $258.00 $86.00 (67%) | 🛒 Add to cart |
| 90 | $1.24 | $387.00 $111.80 (71%) | 🛒 Add to cart |
| 120 | $1.15 | $516.00 $137.60 (73%) | 🛒 Add to cart |
| 180 | $1.05 | $774.00 $189.20 (76%) | 🛒 Add to cart |
| 270 | $0.86 | $1161.00 $232.20 (80%) | 🛒 Add to cart |
| 360 | $0.73
Best per pill | $1548.00 $262.30 (83%) | 🛒 Add to cart |
Similar products
Femalegra represents a significant advancement in addressing female sexual dysfunction, specifically formulated to enhance libido and improve sexual satisfaction. This prescription medication contains sildenafil citrate, a well-established phosphodiesterase type 5 (PDE5) inhibitor that has been specifically studied for its application in female sexual health. Unlike many over-the-counter supplements, Femalegra undergoes rigorous pharmaceutical testing and requires medical supervision, ensuring both safety and efficacy for appropriate candidates. Clinical studies have demonstrated its potential to address physiological aspects of female sexual arousal, making it a valuable option within comprehensive treatment approaches for hypoactive sexual desire disorder.
Features
- Contains 100mg sildenafil citrate per tablet
- Film-coated oral formulation for optimal absorption
- Manufactured in FDA-approved facilities following GMP standards
- Rapid onset of action (typically 30-60 minutes)
- Duration of effect lasting 4-6 hours
- Precisely calibrated dosage for female physiology
- Third-party tested for purity and consistency
- Tamper-evident packaging
Benefits
- Enhances genital blood flow and lubrication response
- Improves subjective arousal and sexual satisfaction
- Supports physiological aspects of sexual response
- May reduce anxiety related to sexual performance
- Complements psychological interventions for sexual dysfunction
- Provides predictable, dose-dependent effects
Common use
Femalegra is primarily prescribed for premenopausal women experiencing acquired, generalized hypoactive sexual desire disorder (HSDD) with accompanying arousal difficulties. It is typically used on an as-needed basis approximately 30-60 minutes before anticipated sexual activity. The medication addresses the physiological component of sexual response by enhancing blood flow to genital tissues, which may facilitate natural lubrication and sensitivity. Patients often use Femalegra in conjunction with non-pharmacological approaches, including relationship counseling, stress management techniques, and sexual therapy, as part of a comprehensive treatment plan.
Dosage and direction
The standard recommended dosage is 100mg taken orally with a full glass of water approximately 30-60 minutes before sexual activity. Administration with a high-fat meal may delay absorption and reduce peak concentration. The tablet should be swallowed whole and not crushed or chewed. Dosage adjustments may be necessary based on individual response and tolerability, particularly for patients with hepatic impairment or those taking concomitant medications that affect sildenafil metabolism. The maximum recommended dosing frequency is once per day. Healthcare providers may initiate treatment at a lower dose (50mg) for patients who experience side effects or have specific medical considerations.
Precautions
Patients should undergo thorough cardiovascular assessment before initiation, as sexual activity carries potential cardiac risk for individuals with pre-existing cardiovascular disease. Those with anatomical deformation of the penis (e.g., Peyronie’s disease) or conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma) should use caution. Ophthalmic examinations are recommended for patients with retinitis pigmentosa or other retinal disorders. Blood pressure monitoring is advised, particularly for patients taking antihypertensive medications. Alcohol consumption should be limited as it may increase the risk of orthostatic hypotension. The medication does not protect against sexually transmitted infections.
Contraindications
Femalegra is contraindicated in patients using any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate) or nitric oxide donors due to the risk of profound hypotension. Additional contraindications include hypersensitivity to sildenafil or any component of the formulation, severe hepatic impairment (Child-Pugh class C), severe hypotension (BP <90/50 mmHg), recent stroke or myocardial infarction (within 6 months), unstable angina, and hereditary degenerative retinal disorders. Concomitant use with riociguat is contraindicated due to potential hypotensive effects.
Possible side effects
The most commonly reported adverse effects (>10% incidence) include headache, flushing, and dyspepsia. Less frequent side effects (1-10% incidence) comprise nasal congestion, dizziness, visual disturbances (including altered color perception, blurred vision, photophobia), back pain, myalgia, and nausea. Rare but serious adverse events (<1% incidence) may include priapism (prolonged erection), sudden hearing loss, non-arteritic anterior ischemic optic neuropathy (NAION), and serious cardiovascular events. Most side effects are dose-dependent and transient, typically resolving within several hours. Patients should seek immediate medical attention for erections lasting more than 4 hours or sudden vision/hearing changes.
Drug interaction
Sildenafil is primarily metabolized by CYP3A4 and CYP2C9 isoenzymes. Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) significantly increase sildenafil exposure—dose reduction to 25mg is recommended. Moderate CYP3A4 inhibitors (e.g., erythromycin, saquinavir) may increase concentrations—consider 50mg starting dose. Alpha-blockers may potentiate hypotensive effects; separate administration by至少 4 hours. Other interactions include potentiation of hypotensive effects with antihypertensives, increased sildenafil levels with CYP3A4 inhibitors, and reduced efficacy with CYP3A4 inducers (e.g., rifampin). Grapefruit juice may increase bioavailability and should be avoided.
Missed dose
As Femalegra is taken on an as-needed basis rather than a scheduled regimen, the concept of a “missed dose” does not directly apply. Patients should take the medication approximately 30-60 minutes before anticipated sexual activity. If sexual activity does not occur after taking the medication, no additional dose should be taken within 24 hours. The medication should not be taken more than once daily regardless of timing relative to planned sexual activity.
Overdose
In cases of overdose, standard supportive measures should be employed. Expected effects would mirror the known adverse reaction profile but with greater severity, particularly regarding hypotension. Management includes maintaining cardiovascular stability through fluid replacement and positioning. Hemodialysis is not expected to significantly enhance elimination due to high protein binding and extensive tissue distribution. Symptomatic treatment for headache, flushing, and gastrointestinal distress may be indicated. Medical supervision is recommended for ingestions significantly exceeding the maximum recommended dose (200mg within 24 hours).
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light and moisture. Keep in the original container with the lid tightly closed. Do not remove desiccant from the packaging. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of unused medication through drug take-back programs or according to FDA guidelines.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Femalegra is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual results may vary. The medication is not intended for use by men, children, or women who are pregnant or breastfeeding. Patients should disclose their complete medical history and current medications to their healthcare provider before initiation. This product is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
Clinical studies involving sildenafil for female sexual dysfunction have demonstrated mixed results, with some trials showing significant improvement in physiological parameters and subjective arousal measures. In a randomized controlled trial published in the Journal of the American Medical Association, women taking sildenafil reported improved genital sensation and overall satisfaction compared to placebo. However, response variability appears greater in female populations compared to male counterparts, likely due to the complex interplay of psychological, relational, and physiological factors in female sexual response. Many clinicians report that patients who respond best are those with predominantly physiological arousal concerns rather than primary desire disorders. Real-world evidence suggests approximately 40-60% of women experience meaningful improvement when Femalegra is integrated into a comprehensive treatment approach.